

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-22. (canceled)

23. (currently amended) A method for enhancing cognitive function and alleviating mental fatigue in a subject, ~~said method~~ comprising administering[[],] to a subject in need thereof[[],] an effective amount of a Ginkgo-phospholipid complex, said complex comprising Ginkgo complexed with a phospholipid, said phospholipid comprising ~~containing~~ 20% phosphatidylserine.

24-25. (canceled)

26. (previously presented) The method according to claim 23, wherein the Ginkgo is derived from the plant *Ginkgo biloba*, extracts thereof and/or one or more principal active substances thereof.

27. (previously presented) The method according to claim 26, wherein one of the principal active substances is bilobalide.

28. (currently amended) The method according to claim 26, wherein the Ginkgo extract ~~contains~~ comprises at least 20% Ginkgo flavone glycosides and ~~about~~ 2-10% terpene lactones.

29. (currently amended) The method according to claim 23, wherein the ~~ratio between~~ Ginkgo and the phosphatidylserine in the complex are in a ratio is of about 1:3.

30. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement that is administered to the subject in the form of tablets, granules, powders, capsules, syrups, solutions, suspensions, dragees, gels, injections or drops.

31. (previously presented) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement and is formulated for oral administration.

32. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement that is administered in an amount of about 20-240 mg per day, ~~or in an amount of about 60-120 mg per day.~~

33. (currently amended) The method according to claim 23, wherein the Ginkgo-phospholipid complex is in a medicament or a dietary supplement, and further ~~contains~~ comprises a pharmaceutically acceptable amount of at least one additive selected from the group consisting of minerals, vitamins, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.

34. (previously presented) The method according to claim 33, wherein the additive is selected from the group consisting of calcium, fluorine, phosphorus, copper, potassium, manganese, magnesium selenium, zinc and iron, Vitamin A, Vitamins B1, B2 and B12, Vitamin C, Vitamin D2, nicotinamide, calcium pantotenate, rutoside and Vitamin E.

35. (currently amended) A method for improving memory speed and memory quality in a normal, healthy human, or reducing deterioration of memory speed and memory quality in a human with decreased cognitive functions, ~~said~~ method comprising administering[[,]] to a subject in need thereof[[,]] an effective amount of Ginkgo complexed with phosphatidylserine.

36. (currently amended) A method for treating a disease related to reduced cognitive function and increased mental fatigue in a subject, ~~said~~ method comprising

administering[[,]] to a subject in need thereof[[,]] an effective amount of Ginkgo complexed with phosphatidylserine.

37. (previously presented) The method according to claim 36, wherein the disease is Dementia.

38. (currently amended) The method according to claim [[37]] 36, wherein the disease is Alzheimer's Disease.

39. (currently amended) The method according to claim 36, wherein the Ginkgo-phosphatidylserine complex is in a medicament or a dietary supplement, and further ~~contains~~ comprises a pharmaceutically acceptable amount of at least one additive selected from the group consisting of vitamins, minerals, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.

40. (previously presented) The method according to claim 36, further comprising administering an additional pharmaceutical compound used for treating the disease related to reduced cognitive function and increased mental fatigue.

41. (previously presented) The method according to claim 40, wherein the additional pharmaceutical compound is an acetylcholinesterase inhibitor.

42. (currently amended) The method according to claim [[40]] 36, further comprising administering complexed grape seed extract, as an additionally active compound, to the subject.

43-45. (canceled)

46. (currently amended) The method of according to claim 23, wherein the ~~ratio between~~ Ginkgo and phosphatidylserine ~~is in the complex are in a ratio of~~ 0.5-1 : 2-5.